Gb Sciences Granted U.S. Patent for Cannabinoid-Containing Treatment for Advanced Heart Disease, TRPV1-Receptor-Associated Hearing Loss and Urinary Cystitis LAS VEGAS, March 01, 2022 (GLOBE NEWSWIRE) -- Gb Sciences, Inc. (OTCQB:GBLX), a leading plant-inspired, biopharmaceutical research and development company, has been issued a new patent today by the...

Gb Sciences Targets COVID-19 Treatment as Omicron Variant Arrives LAS VEGAS, Dec. 06, 2021 (GLOBE NEWSWIRE) -- Gb Sciences, a plant-based research and biopharma technology company, has reported positive results from a study of its potential treatment for cytokine...

Gb Sciences Accelerates Drug Development via Innovative Biopharma Technology and Strategic Partnerships LAS VEGAS, Nov. 29, 2021 (GLOBE NEWSWIRE) -- Recognizing the glacial pace of traditional drug research and development processes and the adverse effect of this on patients, biopharmaceutical company...

Gb Sciences Starts Preclinical Study for Plant-Based Formulas to Treat Depression and Anxiety LAS VEGAS, Nov. 01, 2021 (GLOBE NEWSWIRE) -- Gb Sciences, Inc. ("GbS"; OTCQB:GBLX), a leading plant-inspired research and biopharmaceutical drug development company, has initiated new preclinical...

ORION BIOTECHNOLOGY SUCCESSFULLY COMPLETES PHASE I CLINICAL STUDY OF 0B-002H TOPICAL GEL FOR HIV PREVENTION Ottawa, Canada, April 30, 2020 (GLOBE NEWSWIRE) -- Orion Biotechnology Canada Ltd., a clinical stage pharmaceutical company focused on precision engineering small protein therapeutics, today...